Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B

Exclusion Criteria

• •the history of antiviral therapy for chronic hepatitis B within the recent 6 months
• •HAV IgM Ab + and/or HCV Ab + and/or HDV Ab and/or HIV Ab +
• •the sign of decompensated liver disease
• •the history of hemoglobinopathy, autoimmune hepatitis, alcoholic liver disease
• •pregnant or lactating woman
• •neutrophil count less than 1,500/mm3 or platelet count less than 90,000/mm3
• •serum creatinine more than 1.5 times upper normal limit value
• •the sign of alcoholic or drug addiction within the recent 1 year
• •the history of psychotic disorder especially like depression
• •immunologically mediated disease
• •the history of esophageal varix
• •the history of severe heart disease or respiratory disease
• •the history of severe epilepsy or current use of antiepileptic drug
• •the sign of malignancy or suggestive of malignancy or the history of malignancy, the recurrence rate within 2 years of which is more than 20%
• •the history of systemic anticancer treatment including radiation therapy or immunotherapy including systemic corticosteroid
• •the history of major organ transplantation
• •the history of medically uncontrolled thyroid disease
• •the history or sign of severe retinopathy